Publications & press
News & updates
Oxylanthanum Carbonate Achieves Serum Phosphate Control with Significantly Lower Pill Burden in Dialysis Patients with Hyperphosphatemia
A Phase 2 Clinical Trial of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia – CJASN Manuscript – July 2025
Video: Interview with Dr. Glenn Chertow
AJN: High Phosphate-Binding Capacity of oxylanthanum carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders
Video: Our Lead Asset (Oxylanthanum Carbonate)
Two-Way Randomized Crossover Study to Establish Pharmacodynamic Bioequivalence Between oxylanthanum carbonate and Lanthanum Carbonate
EC Pharmacology and Toxicology: Evaluation of UNI-494 in Acute Kidney Injury Treatment Efficacy When Administered After Ischemia-Reperfusion in a Rat Model
Pharmaceutical Chemistry Journal: Systemic Absorption of Oxylanthanum Carbonate is Minimal in Preclinical Models
Combination Oxylanthanum Carbonate and Tenapanor Synergistically Lowers Urinary Phosphate Excretion in Rats
UNI-494 Phase I Safety, Tolerability, and Pharmacokinetics
Intravenous UNI-494 Slows the Progression or Halts/Reverses Acute Kidney Injury When Administered After Ischemia/Reperfusion in Rats
Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia
Oral Administration of UNI-494 Ameliorates Acute Kidney Injury in a Rat Model of Delayed Graft Function
Enhanced Urinary Phosphorous Reduction: Comparative Study of Oxylanthanum Carbonate and Tenapanor in Rats
UNI-494 Phase I Safety, Tolerability and Pharmacokinetics: Trial in Progress
Oxylanthanum Carbonate for Hyperphosphatemia in ESKD: Tolerability Trial in Progress
Renal Dietitians Perceive Phosphate Binder and Low Phosphorus Diet Non-Compliance as Top Reasons for Above Target Serum Phosphorus Concentrations
Two-Way Crossover Study to Establish Pharmacodynamic Bioequivalence Between OxylanthanumCarbonate and Lanthanum Carbonate
Video: About Unicycive
